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CASE FINDING FOR PULMONARY TUBERCULOSIS AMONG PEOPLE WHO 
INJECT DRUGS IN DAR ES SALAAM, TANZANIA. Akash Gupta. Jessie Mbwambo. 
Ibrahim Mteza. Sheela Shenoi. Barrott Lambdin. Cassian Nyandindi. Basra Ismail Doula, 
Said Mfaume, and Robert Douglas Bruce. Department of Internal Medicine, Yale 
University, School of Medicine, New Haven, CT.  
  
 Active case finding is a World Health Organization (WHO)-endorsed strategy for 
improving case detection of tuberculosis. Despite WHO recommendations for active case 
finding among people who inject drugs (PWID), there are few published studies. The 
historical focus of case finding has been in populations that are HIV-positive, 
incarcerated, or at higher occupational risk. We sought to examine the yield of active case 
finding among PWID newly started on methadone in Tanzania.  
 A questionnaire including tuberculosis symptoms and risk factors was 
administered to every consenting patient by a native Swahili-speaker. Additional chart 
review was performed for demographic information and HIV status. Two sputum 
samples were collected for every symptomatic patient, and samples were tested using 
smear microscopy as well as culture.   
 A total of 156 of 222 (70%) methadone clients met with study administrators; 150 
of whom consented to the study. Median age was 34 years old, and 139 (93%) were male. 
Thirty-four (23%) were HIV-positive, and an additional 104 (69%) had an unknown HIV 
status. Of the 150 patients surveyed, 16 (11%) had one or more tuberculosis symptoms 
and were referred for laboratory testing. Six new cases of tuberculosis were identified, 5 
of which were sputum smear-negative, and 1 of which was multi-drug resistant. The 
prevalence of tuberculosis was 4%  
 This study presents the first data on tuberculosis prevalence in a population of 
PWID in Tanzania. This prevalence is 23 times the general Tanzanian tuberculosis 
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prevalence of 0.2%.  PWID in Tanzania should continue to be screened for tuberculosis 
with smear, culture and drug susceptibility testing. Screening should expand to PWID in 
the community.  
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Introduction 
History of Tuberculosis 
Tuberculosis (TB) is a devastating infectious disease that has been infecting mankind for 
many millennia. The oldest skeletal remains of a TB patient come from Liguria, Italy 
around 5800 BCE.(1) The first written records come from ancient Egypt, where 
physicians first described the disease.(2) Investigators have found DNA evidence of the 
mycobacteria in Egyptian mummies buried between 2050 BC to 500 BC.(3) Hippocrates 
in Greece labeled the disease “phthisis”(2), and the disease appears often in Western 
literature as “consumption”(4). In 17th century London, the disease became so prevalent 
and had such high mortality that the English preacher John Bunyan dubbed TB, “The 
Captain among these men of death”.(5) The industrial revolution brought increasingly 
crowded living conditions, drastically increasing TB transmission and incidence in 
Europe.(2) In London, 1 in 7 deaths were caused by TB at the beginning of the 18th 
century, 1 in 5.25 in the middle, and 1 in 4.2 by the end of the century.(6) TB caused 25% 
of deaths in Europe in the 19th century(5). Despite this large societal burden, the 
causative pathogen, Mycobacterium tuberculosis, was not discovered until 1882 by 
Robert Koch in Germany.(2)  
 
In the 20th century, the developed world saw improvements in the TB death toll due to 
better living standards, including improved nutrition, income, and less crowded housing 
conditions.(5) Additionally, antimicrobial treatment was developed in the 1940s with the 
discovery of streptomycin, evolving into a multi-drug therapy regimen of several 
different antibiotics, greatly improving treatment outcomes from the era of sanatorium 
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and surgery-based care.(2) However, the advent of the HIV epidemic in the 1980s fueled 
a resurgence of TB, especially in Sub-Saharan Africa. TB control efforts now face the 
challenges of HIV/TB coinfection, drug-resistant organisms, inadequate diagnostic tests, 
and weak health systems in the countries most affected.(5)  
 
Disease Characteristics 
It is now known that the disease can be caused by a group of bacteria known as the 
Mycobacterium tuberculosis complex, including Mycobacterium tuberculosis, 
Mycobacterium africanum, Mycobacterium bovis, Mycobacterium microti, and 
Mycobacterium canetti. Before milk pasteurization became routine, Mycobacterium bovis 
caused up to 6% of TB cases.(5) After the Mycobacteria infect a human, most 
immunocompetent individuals either eliminate the bacteria or contain it in an inactive 
state called latent TB infection (LTBI).(5) Active TB disease is most commonly caused 
by reactivation of a latent infection, when the organism multiplies to cause pathology and 
active, symptomatic disease.(7) In an immunocompetent host the lifetime risk of 
reactivation is approximately 10%, with the greatest risk in the first few years after initial 
infection.(5) However, the reactivation risk is about 10% per year in HIV-infected 
persons.(8)  in patients with impaired immunity, such as individuals with HIV. Recent 
research suggests that the binary division between latent and active disease states may be 
overly simplistic, and that many patients may exist on a spectrum between latent and 
active disease.(5)  
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Active TB manifests most commonly as pulmonary infection, resulting in cough with 
sputum production and/or hemoptysis. However, TB can cause disease in almost any 
body tissue, manifesting with organ-specific symptoms. Additionally, the disease often 
causes constitutional symptoms, including fevers, night sweats, and severe weight loss. 
Extrapulmonary and disseminated miliary TB is more common among HIV-infected 
individuals. (9) 
 
Tuberculosis Diagnostics: 
TB control efforts are significantly hampered by the lack of accurate and rapid 
diagnostics. For latent TB, the standard test for over a century has been Tuberculin Skin 
Testing (TST), which relies on delayed-type hypersensitivity immune response to 
mycobacteria placed intradermally.(10) However, the TST has several drawbacks. First, 
it requires patients to return in 48-72 to read the result, which can result in a loss-to-
follow-up, especially in hard-to-reach populations such as homeless individuals and 
people who inject drugs and in resource-limited settings.(11) Secondly, TST can be 
affected by receipt of the BCG vaccine, which is currently given to more than 90% of 
children worldwide. Third, TST is not specific to TB and therefore can be positive in 
response to mycobacteria other than tuberculosis (MOTT).(10)  
 
In more recent years, a second test for latent TB has been developed, called the 
Interferon-Gamma Release Assay (IGRA). This is a serum test that measures interferon-
gamma release by T-cells in response to stimulation with the TB antigens ESAT-6 and 
CFP-10. IGRA has several advantages over TST testing: it is more specific, not affected 
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by prior administration of the BCG vaccine, and less affected by most environmental 
mycobacteria. Additionally, it does not require a follow-up visit, which is advantageous 
in hard-to-reach populations. The test is expensive, and requires access to a sophisticated 
laboratory – a serious liability in resource constrained areas.(11) Although there is 
evidence that it has high sensitivity in patients with active disease, it cannot distinguish 
between latent and active TB.(5) IGRA’s cannot reliably distinguish between treated 
prior infection and reinfection, and cannot be used to reliably predict who is at risk of 
progressing to active disease.(12)  
 
For active TB, culture of the organism is the most sensitive test, and is the current 
diagnostic gold standard. Although liquid culture systems are preferable due to faster 
turnaround time and higher yield, they are prohibitively expensive in many settings, and 
solid agar is still widely used. Conventional drug susceptibility testing (DST) requires 
culturing the organism. However, culture diagnosis takes a long time – even with the 
newer automated liquid culture systems, diagnosis still takes a minimum of 10-15 
days.(13) This is due to the extremely slow doubling rate of Mycobacterium tuberculosis, 
which divides once every 15-20 hours.(5) 
 
Most low and middle-income countries rely heavily on a combination of sputum smear 
microscopy and chest x-ray for diagnosis.(5) For sputum smear microscopy, the 
conventional Ziehl-Neelsen staining method was invented in the 1880s shortly after Koch 
first discovered the bacterium.(2) Although the results for sputum smear microscopy are 
relatively rapid, sensitivity ranges between 50 to 80%, and is subject to operator 
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performance.(13) Additionally, HIV can further decrease the likelihood of smear-positive 
TB.(14) The development of fluorescent microscopy with Auramine O increases the 
sensitivity, and can increase the efficiency of microscopy.(15)  
 
More recently, Nucleic Acid Amplification Tests (NAATs) have been developed for 
active TB diagnosis. These tests are PCR-based, and offer many advantages to 
conventional microscopy and culture. Cepheid has recently developed the GeneXpert 
assay, which is a cartridge-based, automated test that can test for presence of 
Mycobacterium tuberculosis and simultaneously test for rifampicin resistance. The test 
can be performed with minimum laboratory expertise, and results can be available within 
2 hours. In smear-positive patients, the assay has sensitivity of 98%. In smear-negative 
patients, the assay has sensitivities of 72.5%, 85.1%, and 90.2% on one, two, and three 
samples, respectively. Specificity is high at 99.2%.(16) In HIV-positive individuals, one 
study found an Xpert sensitivity of 66.4% when screening patients eligible for 
antiretroviral therapy in Ethiopia.(17) Among HIV-positive patients with a high clinical 
suspicion for TB in Peru, sensitivity was high as 97.8%, with a specificity of 97.7%.(18)  
The assay is also highly accurate for detection of rifampicin resistance, as long as the 
predominant strain of bacteria present in the sample is rifampicin-resistant. The threshold 
number of colony-forming units (CFUs) required for mycobacterial detection is much 
lower than smear microscopy, similar to solid culture, but less than liquid culture. As 
with any new technology, there are limitations. First, it cannot be used to monitor 
response to therapy, as it will detect killed organisms. Second, it is very expensive. 
Finally, although the turnaround time for diagnosis is significantly faster than for other 
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methods of diagnosis, it is still not quite point-of-care, which can make same-day clinical 
decisions difficult in crowded health facilities. Nevertheless, it represents a significant 
advance for TB diagnosis.(16) 
 
Tuberculosis Treatment:  
For patients with active TB, the World Health Organization (WHO) recommends as first-
line therapy a combination of rifampicin, isoniazid, pyrazinamide, and ethambutol for 2 
months, followed by rifampin and isoniazid for another 4 months. Since the early 1990s, 
the WHO has endorsed Directly Observed Therapy (DOT) to improve medication 
adherence and successful treatment completion.(19)  
 
Unfortunately, the world has seen the emergence of drug-resistant strains of TB, which 
are much more difficult to treat. Strains that are resistant to both rifampicin and isoniazid, 
which often co-occur, are called Multi-Drug Resistant Tuberculosis (MDR-TB). For 
MDR-TB, the WHO recommends using at least 4 drugs certain to be effective. The 
groups of drugs are separated into 5 groups: first-line oral agents, injectable agents, 
fluoroquinolones, oral bacteriostatic second-line agents, and 3rd line agents with unclear 
role in the treatment of drug-resistant TB. Choosing the correct drug regimen can be 
informed by DST testing for drugs that have good laboratory reliability, such as 
injectable agents and fluoroquinolones. Alternatively, it can be based on survey data 
showing rarity of resistance to the drug, or can be a drug that is not commonly used in the 
area. MDR-TB treatment regimens last for a minimum of 18 months from the last 
negative culture.(19)   
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Most worryingly, strains resistant to even more drugs have emerged. A strain is called 
“Extensively drug resistant” (XDR-TB) if it is resistant to isoniazid and rifampin, plus 
any fluoroquinolone and at least one of three injectable second-line agents. Therapy for 
this category is complex, and outcomes are highly variable.(20)  
 
TB antimicrobial therapy went through a period of innovation in the 1940s-1960s. 
However, as TB became a less urgent threat in the developed world, drug development 
stalled. In the face of rising resistance, TB therapy has suffered from this lack of novel 
therapeutics. However, recently a drug called bedaquiline was approved by the FDA for 
TB treatment in 2012, the first new drug for TB in over forty years. Other agents are 
currently in the drug development pipeline.(21)  
    
Global Epidemiology 
An estimated 2 billion people worldwide are latently infected with Mycobacterium 
tuberculosis.(5) In the year 2013, there were an estimated 9.0 million new cases of active 
TB, for an incidence of 126 per 100,000 population. The South-East Asia and Western 
Pacific regions account for more than half (56%) of TB cases. About 1.1 million cases 
(13%) were co-infected with HIV. Globally in 2013, there were about 1.5 million deaths 
from TB, and 360,000 (24%) of these were co-infected with HIV.(22)  
 
The African region is suffering the worst burden of disease. Although the region only 
accounts for about a quarter of total incidence cases in 2013, it has the highest prevalence 
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(300 per 100,000) incidence (280 cases per 100,000), and mortality (32 per 100,000 
among HIV/TB coinfected people, and 42 per 100,000 excluding that group). The 
African region also has the highest proportion of TB cases (34%) that are co-infected 
with HIV.(22) 
 
Globally, an estimated 5% of TB cases are estimated to be MDR-TB. Among new TB 
cases in 2013, the estimated proportion of MDR-TB cases was 3.5%. Trend analysis 
shows that the overall proportion of MDR-TB cases has not changed between 2008 to 
2013, staying at about 3.5%. However, some countries have serious MDR-TB epidemics. 
These include many countries of Eastern Europe. In Belarus, for example, an estimated 
35% of new TB cases are MDR-TB, and an estimated 55% of cases undergoing 
retreatment are MDR-TB. More than half the global burden of MDR-TB is in three 
countries: India, China, and the Russian Federation.(23)  
 
XDR-TB was first described in 2006, after an alarming report by Gandhi and colleagues 
of an XDR-TB epidemic in the town of Tugela Ferry in the province of KwaZulu-Natal, 
South Africa, where 53 of 1539 (6%) patients were found to have XDR-TB over a 1-year 
period. Fifty-two of these patients died, 70% in the first 30 days after sputum 
collection.(24) Since this report, 100 countries have reported at least one XDR-TB case 
as of 2013.(23)  
 
As discussed above, the largest risk factor for TB is HIV, which greatly increases 
susceptibility to infection, primary progressive disease, reactivation, and recurrence. 
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Other risk factors include diabetes, malnutrition, overcrowded living conditions, 
smoking, indoor air pollution, silicosis, alcohol, and immunosuppressive drugs, such as 
corticosteroids and TNF antagonists.(5)  
 
Certain social groups have been historically associated with TB, especially in countries 
where the disease is not endemic. In the USA, for example, these include people with a 
history of homelessness(25), incarceration(26), or foreign-born from an endemic 
country(27). Another major high-risk population is people who use illicit drugs.(28)    
 
Tuberculosis in People Who Use Illicit Drugs:  
Drug use is associated with both a higher prevalence of latent TB infection and higher 
incidence of TB disease.(28-30) Drug users are more likely to be infectious, to take 
longer to achieve negative culture, and to be at increased risk of mortality from TB. In 
some studies, duration of injection drug use and older age were most commonly 
associated with latent TB. There is also evidence of increased rates of transmission 
among drug users, and there have been outbreaks among people who use drugs in many 
countries around the world. (28) 
 
Drug use was described as a risk factor for TB even before the HIV era, in a study by 
Reichman and colleagues based in New York City in the 1970s.(31) One potential 
explanation for this association is from the immunosuppressive effects of certain illicit 
drugs. For example, opiates may directly impair the cell-mediated immune response. 
Additionally, drug use is associated with other behaviors and risk factors that overlap 
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with TB, including tobacco use, homelessness, alcohol abuse, and incarceration. 
Additionally, crowded venues for drug use with poor ventilation may serve as sites of 
transmission.  TB outbreaks have also been associated with sharing drug equipment, and 
the practice of “shotgunning” (inhaling and exhaling smoke directly into another’s 
mouth).(28)  
 
Studies show mixed results on whether people who inject drugs (PWID) have an 
increased risk for latent TB over non-injectors. However, PWID are at increased risk of 
HIV from needle-sharing based transmission, and this confers a significantly increased 
risk of active TB disease. HIV-infected PWID may even be at increased risk of TB 
infection and disease compared with other HIV-infected individuals.(28)  
 
In addition to this TB risk, PWID are at increased risk for many poor health outcomes, 
including viral hepatitis, bacterial soft tissue infections, infective endocarditis, and 
overdose.(32, 33) PWID worldwide are estimated to have a 14.7 times the mortality risk 
of the general population.(32)  
 
For all of these reasons, PWID are an important target group for medical and public 
health services. However, due to many barriers including social stigma, unstable 
lifestyles, lack of health insurance, worries about narcotic withdrawal, poor knowledge of 
TB transmission, and provider perceptions, PWID have been a hard-to-reach population 
for most health systems.(28)    
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Tuberculosis Case Finding:  
Surveillance for active TB relies largely on passive case finding, in which symptomatic 
patients present to healthcare sites for evaluation of disease.(34) The benefits of 
community-based population screening for active TB is debated, with studies showing 
mixed results on improvement in community TB prevalence.(35-37) However, passive 
case finding may be insufficient for certain high-risk groups, in whom TB burden is 
particularly high, or who do not regularly interface with the health system by their own 
volition. The WHO has strong recommendations to systematically screen households and 
other close contacts of TB cases, people living with HIV, and people with workplace 
exposure to silica. WHO also conditionally recommends screening prisoners, people 
living in high prevalence areas, and populations with poor access to healthcare, including 
homeless people, people living in urban slums or remote areas, and other vulnerable or 
marginalized groups.(34)  
 
For the reasons specified above, people who use drugs are another group in whom active 
case finding can be beneficial. The WHO issued recommendations in 2008 for 
collaborative TB and HIV services for drug users. They recommend that all services 
dealing with drug users have a case-finding protocol for TB and HIV. At a minimum, the 
WHO recommends including a simple set of questions on the symptoms and signs of TB 
as a basis for active case finding at facilities providing services to drug users.(38)  
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Programmatically, different active case finding programs choose whether to start with a 
symptom screen or to screen all program participants with chest radiography or sputum 
collection. Symptom screens are simpler and cheaper to implement, but risk missing 
asymptomatic cases.  Similarly, programs have to choose whether to limit to sputum 
smear analysis versus also culturing all collected sputum specimens. Sputum smear is 
cheaper and requires less trained personnel than culture, but using smear microscopy 
alone risks missing smear-negative TB. Culture is also required for drug susceptibility 
testing to detect drug-resistant TB. The best protocol for active case finding is debated, 
and often comes down to a decision based on local factors, such as available funding, 
laboratory capacity, and prevalence of HIV. (34, 39) For the purposes of determining 
isoniazid preventive therapy (IPT) eligibility among people living with HIV in resource-
constrained settings, the WHO recommends symptom-based case finding at facilities, 
with the absence of four key symptoms enough to rule out active TB.(40) This conclusion 
was based on a study by Getahun and colleagues in 2010 that found the absence of 
current cough, fever, night sweats, and weight loss can identify a subset of people living 
with HIV who have a very low probability of having active TB.(41)      
 
Tuberculosis in Tanzania: 
Tanzania ranks 18th out of the	  22	  countries	  that	  have	  been	  labeled	  high-­‐burden	  countries	  by	   the	  WHO.	  Together,	   these	  countries	  account	   for	  80%	  of	   the	  world’s	  TB	  cases.	  In 2013, 
the World Health Organization (WHO) estimated TB prevalence in Tanzania of 85,000 
(172 per 100,000) and an incidence of 81,000 (164 per 100,000), with 1.1% of new cases 
being multi-drug resistant (MDR). Significantly,	   37%	   of	   the	   tested	   TB	   patients	   are	   HIV-­‐infected.	  As	  the	  first	  African	  country	  to	  implement	  Directly	  Observed	  Therapy	  (DOTS)	  under	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the	  WHO,	   Tanzania	   has	   a	   relatively	  well-­‐developed	   infrastructure	   for	   TB	   treatment,	  with	  treatment	   success	   rate	   of	   90%.	   Despite	   this,	   there	   is	   an	   annual	   mortality	   of	   6000	   HIV-­‐negative	  TB	  cases,	  with	  an	  additional	  mortality	  of	  6100	  in	  HIV/TB	  coinfected	  patients.	  (22)	  	  
	  
Drug Injection in Tanzania and Study Rationale:  
East Africa has been an important stop along international drug trafficking routes for 
three decades. The United Nations Office on Drugs and Crime (UNODC) predicts that 
40-45 tons of Afghan heroin were trafficked to Africa in 2009, the majority entering East 
African ports from Pakistan, Iran, the United Arab Emirates, and India. The trade appears 
to be run by Nigerian traffickers, with heroin being transported through Nigeria before 
being shipped to Europe. However, users in Africa consume an estimated 34 tons of 
heroin, with only 7 tons being shipped onwards to Europe. UNODC estimated in 2011 
that there are 1,736,000 heroin users in Africa, with approximately one-third residing in 
Eastern Africa.(42)  
 
In Tanzania, there were an estimated 200,000 – 250,000 individuals using heroin in 
Tanzania, with approximately 40,000 injectors as of 2005.(43) The epidemics of TB and 
human immunodeficiency virus (HIV) are particularly intertwined with heroin addiction 
in Tanzania. While the 2012 estimate of HIV prevalence in the Tanzanian general 
population was 5.1%(44), an estimated 42% of people who inject drugs (PWID) in Dar es 
Salaam have HIV.(45)  
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The Tanzanian AIDS Prevention Programme introduced methadone-based Medication-
Assisted Treatment (MAT) in 2011 at Muhimbili National Hospital in Dar es Salaam, 
Tanzania. The goal of the program was to address heroin addiction with the goal of 
reducing injection drug use, preventing HIV, and helping those with HIV to engage in 
care and treatment. This was the first public methadone clinic in sub-Saharan Africa, and 
all clients were heroin injectors. Patients were referred to the MAT clinic by Non-
Governmental Organizations (NGOs) that worked with PWID in the community.  
 
In the first 4 months the clinic operated prior to our project, three patients had already 
been diagnosed with pulmonary TB. One of these patients was hospitalized with severe 
symptoms and ultimately died. This prompted significant concern that other patients 
could have undiagnosed TB. The clinic staff was worried that these undiagnosed cases 
could be lethal without early treatment, and could pose an infection risk to fellow patients 
and healthcare workers.  
 
Statement of Purpose 
In response to concerns about undiagnosed TB in the patients of the MAT program at 
Muhimbili National Hospital, we implemented an active case finding project for 
pulmonary TB with the following goals: 
1) To identify any undiagnosed pulmonary TB cases and link them to treatment 
2) To assess the prevalence of active pulmonary TB in this population of PWID on 
methadone treatment 
3) To determine the prevalence of HIV/TB coinfection in this population 
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4) To determine the proportion of cases with MDR-TB  
5) To determine the proportion of cases that are smear-positive 
6) To describe characteristics of TB cases 
 
Methods: 
Study Design: 
This was a cross-sectional case finding study to determine the prevalence of active 
pulmonary TB cases within a population of Tanzanian PWID on methadone treatment. 
The primary outcome was to determine prevalence of active TB. Secondary outcomes 
included prevalence of HIV/TB coinfection, prevalence of MDR-TB, and prevalence of 
smear-positive TB.  
 
Study Population and Recruitment: 
The study was conducted at the Medically Assisted Treatment (MAT) program in the 
Psychiatry Department at Muhimbili National Hospital, Dar es Salaam. Our study 
population included all 222 registered patients who were regularly attending the MAT 
program as of August 22nd, 2011, when enrollment concluded.  
 
An informational flyer was posted outside the methadone-dispensing window several 
days in advance of the study to inform patients of the upcoming screening. The 
pharmacist directed patients to meet with study administrators on-site after receiving 
methadone. Participants provided informed consent in Swahili prior to screening. Patients 
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that were literate signed a consent form, and patients who could not write provided 
fingerprints on the consent form, consistent with standard practices.  
 
TB Case Finding Protocol: 
A symptom-based questionnaire was adapted from a previous TB survey in Ethiopia, and 
was administered to every consenting patient in Swahili by a native Swahili-speaker. 
Patients were asked about the following symptoms: cough greater than 2 weeks duration 
(with or without sputum, with or without hemoptysis), fever greater than 1 month 
duration, night sweats, weight loss, and change in appetite. If the patient reported a cough 
of less than 2 weeks duration, he or she was asked to return at 2 weeks duration to report 
if the cough had persisted. In addition, patients were asked about past TB history, 
housing and ventilation, and incarceration history (including pre-trial detention).   
 
Any patient reporting one or more symptoms in the questionnaire was referred for 
sputum collection (see Figure 1). Patients were asked to produce two sputum samples: 
one was produced on-site after completion of the questionnaire and without exposure to 
direct sunlight, while one was produced the following morning and delivered to clinic 
staff when arriving for the patient’s methadone. Samples were stored indoors in a cool 
environment out of direct sunlight for no longer than 12 hours. The study administrator 
delivered these samples, without exposure to sunlight, to the Central Tuberculosis 
Reference Laboratory located onsite at Muhimbili National Hospital.  
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Figure 1: Flow Chart of Survey and Laboratory Testing Protocol 
 
 
 
MAT = Medication Assisted Treatment; TB = tuberculosis; MDR = multi-drug resistant. 
 
Sputum smear analysis was performed by a trained technician using Auramine O 
staining. Each sample was cultured using Lowenstein-Jensen solid media (Modified 
Petroff Method). Culture-positive samples underwent Drug Susceptibility Testing (DST) 
against isoniazid, rifampin, streptomycin, and ethambutol. Samples with suspected 
Mycobacteria Other Than Tuberculosis (MOTT) were confirmed by rho-nitrobenzoic 
acid (PNB).  
 
Total	  MAT	  Clients	  
(222)	  
Met	  with	  team	  
(156)	  
Consented,	  	  
Survey	  Administered	  	  
(150)	  
One	  or	  more	  symptoms	  	  
(16)	  
Sputum	  smear	  &	  
culture	  x	  2	  
Smear	  PosiJve,	  
Culture	  PosiJve	  	  
(1)	  
Smear	  NegaJve,	  
Culture	  PosiJve	  
(5)	  
Drug-­‐
SuscepJble	  TB	  
(5)	  
MDR-­‐TB	  
(1)	  
Smear	  NegaJve,	  	  
Culture	  NegaJve	  
(10)	  
AsymptomaJc	  
(134)	  
Did	  not	  consent	  	  
(6)	  
Did	  not	  meet	  with	  team	  
(66)	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TB cases were defined as patients who had either smear or culture evidence of 
Mycobacterium tuberculosis in at least one sputum sample. MDR-TB was defined as 
resistance to isoniazid and rifampin.  
 
Linking Cases to Treatment:  
Clinicians at the MAT program were immediately informed of all patients with smear or 
culture results positive for TB. These patients were referred to the National Tuberculosis 
and Leprosy Programme (NTLP) at Muhimbili National Hospital, which prescribed their 
therapy regimen according to national guidelines. Treatment was delivered on-site along 
with methadone.  
 
Chart Review: 
As part of the MAT clinical program, patients have standardized assessments including 
the Addiction Severity Index (ASI)(46) throughout the course of their treatment. The ASI 
is a standardized instrument developed in 1980 by A. Thomas McLellan, used to 
establish the nature and severity of possible medical, employment, drug, alcohol, legal, 
family, social, and psychiatric problems. Each patient received a baseline ASI survey, 
and monthly follow-up ASI surveys up to 3-months, at which point they were performed 
as needed. A chart review of the ASI was used for demographic history, drug use history, 
legal history, and living situation. If multiple ASI were present, information was taken 
preferentially from the most recent follow-up ASI.  
 
	  	  
23	  
Chart review was also performed for laboratory documentation of HIV status. HIV-
positive status was defined by any prior positive HIV test, whether at the MAT clinic or 
at another facility. HIV negative status was defined by a negative test at the MAT clinic 
within the prior 3 months. All other patients were classified as unknown HIV status. For 
patients not enrolled in our study, we collected basic demographic data from baseline 
registration information and HIV status from laboratory record review.  
 
Data Analysis:  
Data was entered into Microsoft Excel and basic proportions were calculated in Excel. To 
compare characteristics of enrolled vs. unenrolled patients, Stata was used to make 
comparisons using two-sample student’s t-test for means and two-sample test for 
proportions. P values < 0.05 were considered significant.  
 
Ethical Approval 
This study was cleared by two Institutional Review Boards: the Yale University Human 
Investigations Committee granted an exemption, and the Muhimbili University of Health 
and Allied Sciences Senate Research & Publications Committee granted ethical approval. 
 
Role of the Student Author: 
The student author generated the idea for the study in an initial meeting with his thesis 
mentor, Dr. Bruce. He received an active case-finding questionnaire that had been 
recently implemented by a public health student in Ethiopia, and adjusted it to fit the 
Tanzanian setting. He then traveled to Dar es Salaam and worked with the Tanzanian 
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AIDS Prevention Programme to translate the questionnaire into Swahili. He met with 
clinicians, nurses, pharmacists, the Central Tuberculosis Reference Laboratory, and the 
National Tuberculosis and Leprosy Programme to design and refine the protocol and 
workflow. He was present for all patient interviews, and provided clarification and advice 
to the Swahili-speaking interviewer as needed. He supervised the collection of sputum 
specimens, and hand-delivered 90% of the samples to the laboratory. He performed all 
chart review for patients enrolled in the study. Chart review for patients who were not 
enrolled in the study was performed by a data manager at Pangaea Global AIDS 
Foundation. He also implemented a protocol whereby the clinic could continue to screen 
all of its future patients for TB upon registration. The student performed all data entry 
and analysis, and wrote the manuscript, which was published in the International Journal 
of Tuberculosis and Lung Disease in 2014.  
 
Results 
Recruitment:  
From July 28 to August 22, 2011, 156 of 222 (70%) clients met with study 
administrators, of whom 150 consented to this study. Table 1 compares age, sex, HIV 
positivity rate, and prior history of arrest or charge between our sample and the 72 
patients not enrolled in the study. Our sample was older than the unenrolled group (Mean 
34.1 years vs. 31.5 years, p=0.002), and had a significantly higher percentage of known 
HIV-positives (23% vs. 11%, p=0.03). There were no significant differences between 
proportion of male patients and history of prior arrest or legal charge.  
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Table 1: Baseline characteristics for all patients on methadone treatment as of August 
22nd, 2011 at Muhimbili Medication Assisted Treatment Program, Dar es Salaam, 
Tanzania 
Characteristics All registered 
patients 
(n=222) 
Enrolled 
patients (n=150) 
Un-enrolled 
patients (n=72) p 
Mean age in years 
(SD) 33.3 (5.7) 34.1 (5.9) 31.5 (5.1) 0.002 
Male  204 (92%) 139 (93%) 65 (90%) 0.54 
HIV-positive 42 (19%) 34 (23%) 8 (11%) 0.03 
Prior arrest or 
charge 138 (62%) 88 (59%) 50 (69%) 0.12 
Note: all information taken from chart review.  
IQR = Interquartile Range  
 
Background characteristics:  
Demographics, risk factors, and TB history of our sample are summarized in Table 2. 
The median age was 34 years old, with an interquartile range (IQR) of 8. Men comprised 
the largest group with 139 of 150 (93%) participants. Most patients were single (61%), 
with a mean of 1.0 child. The majority of patients had been educated to a Primary (47%) 
or Low Secondary (41%) level. All patients had a prior history of heroin injection, as this 
was required for entry into the methadone program. In addition to heroin, marijuana 
(36%) and alcohol (11%) were the 2 most common substances used. A majority of 
patients (69%) reported staying with others, with a mean of 5 members per household. A 
history of incarceration (including prison, jail, or pre-trial detention) was reported by 107 
(71%) patients.  
 
Chart review demonstrated 34 (23%) HIV-infected patients, and 12 (8%) HIV un-
infected within the previous 3 months. Despite the elevated HIV risk among PWID, 104 
(69%) refused HIV testing, and their status was unknown. A prior history of TB was 
	  	  
26	  
reported by 26 patients (17%), and the median time since previous diagnosis was 5 years, 
with an IQR of 5.5 years. The majority reported a history of pulmonary TB (73%), but 
almost one-quarter (23%) had a history of extrapulmonary TB.  In their previous 
diagnosis of TB, 14 (54%) patients reported diagnosis by laboratory methods, and an 
additional 3 (12%) of patients were diagnosed by both laboratory methods and x-ray. No 
laboratory or clinical data was available to confirm prior TB. Twenty-four (92%) patients 
reported completing a full course of treatment, with 10 (38%) completing an 8-month 
course and 14 (54%) completing a 6-month course. Only two patients (8%) reported a 
history of defaulting on TB treatment. Most (81%) patients said that they had tested 
negative after treatment, but 5 individuals (19%) said that they had never been tested 
after beginning treatment.  
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Table 2: Population demography, tuberculosis risk factors, HIV status, and tuberculosis 
history of patients on methadone treatment at Muhimbili Medication Assisted Treatment 
Program, Dar es Salaam, Tanzania 
 
Characteristics Total Sample     (n = 150) 
Non- tuberculosis 
Patients  
(n=144) 
Tuberculosis 
Patients  
(n = 6) 
Median Age, IQR 34, 8 34, 8 34.5, 6.25 
Gender    
     Male 93% (139/150) 92% (133/144) 100% (6/6) 
     Female 7% (11/150) 8% (11/144) 0% 
Marital Status    
     Single 61% (92/150) 62% (89/144) 50% (3/6) 
     Married 17% (25/150) 16% (23/144) 33% (2/6) 
     Divorced/Separated 20% (30/150) 20% (29/144) 17% (1/6) 
     Widowed 2% (3/150) 2% (3/144) 0% 
Mean Number Children, SD 1.0, 0.9 1.0, 0.9 1.0, 0.9 
Education    
     No Education 0.7% (1/150) 0.7% (1/144) 0 
     Primary 47% (70/150) 46% (66/144) 67% (4/6) 
     Low Secondary 41% (62/150) 42% (60/144) 33% (2/6) 
     Upper Secondary 7% (11/150) 8% (11/144) 0% 
     University 4% (6/150) 4% (6/144) 0% 
     Additional Training* 9% (13/150) 9% (13/144) 0% 
Primary (Non-Heroin) Substance of Abuse     
     None 47% (70/150) 47% (68/144) 33% (2/6) 
     Alcohol 11% (17/150) 10% (15/144) 33% (2/6) 
     Sedatives, Hypnotics, Tranquilizers 4% (6/150) 4% (6/144) 0% 
     Cannabis 36% (54/150) 36% (52/144) 33% (2/6) 
     Polysubstance 2% (3/150) 2% (3/144) 0% 
Housing    
     Own 11% (16/150) 10% (15/144) 17% (1/6) 
     Rent 19% (29/150) 20% (29/144) 0% 
          Mean Rent TSH, SD 37600, 25,700 37600, 25,700 N/A 
     Staying with Others 69% (103/150) 68% (98/144) 83% (5/6) 
     Homeless 1% (2/150) 1% (2/144) 0% 
     Mean Years in Same House, SD 12.0, 14.1 (n=148) 12.0, 14.2 (n=141) 11.4, 13.1   
     Mean Number People, SD 4.9, 2.6  (n=145) 4.9, 2.6  (n=139) 4.6, 2.7 (n=7) 
     Mean Number 
     Windows per Room 1.5, 0.6 (n=148) 1.6, 0.6 (n=142) 1.16, 0.4 
Previously Incarcerated or in Jail** 71% (107/150) 71% (102/144) 83% (5/6) 
Knowledge about tuberculosis (1-5), SD*** 2.4, 1.0 2.4, 1.0 2.0, 0.6 
Risk of tuberculosis (1-5), SD*** 1.8, 1.0 1.8, 1.0 (n=143) 3.5, 0.5 
Effort to Prevent tuberculosis (1-5), SD*** 3.5, 1.2 3.5, 1.2 2.3, 0.5 
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HIV Status    
     HIV Positive 23% (34/150) 22% (31/144) 50% (3/6) 
     HIV Negative 8% (12/150) 8% (11/144) 17% (1/6) 
     HIV Unknown 69% (104/150) 71% (102/144) 33% (2/6) 
Previous History of tuberculosis 17% (26/150) 16% (23/144) 50% (3/6) 
     Years since Last Diagnosis (Median, IQR) 5.0, 5.5 5, 6.5 4.5, 2 
     Type of tuberculosis, Most Recently    
          Pulmonary 73% (19/26) 74% (17/23) 67% (2/3) 
          Extrapulmonary 23% (6/26) 26% (6/23) 33% (1/3) 
          Not Sure 4% (1/26) 4% (1/23) 0% 
     How Diagnosed, Most Recently    
          Laboratory Methods 54% (14/26) 52% (12/23) 67% (2/3) 
          X-ray 35% (9/26) 35% (8/23) 33% (1/3) 
          Laboratory and X-ray 12% (3/26) 13% (3/23) 0% 
     Amount of Treatment, Most Recently      
          Complete, 8 months 38% (10/26) 43% (10/23) 33% (1/3) 
          Complete, 6 months 54% (14/26) 57% (13/23) 33% (1/3) 
          Incomplete, 5-6 months 4% (1/26) 0% (0/23) 33% (1/3) 
          Incomplete, <2 months 4% (1/26) 4% (1/23) 0% 
          Total Completing Treatment 92% (24/26) 96% (22/23) 67% (2/3) 
          Total Defaulting on Treatment 8% (2/26) 4% (1/23) 33% (1/3) 
    Most Recent Test after Treatment    
          Positive 0% 0% (0/23) 0% 
          Negative 81% (21/26) 83% (19/23) 67% (2/3) 
          Not Tested after Beginning Treatment 19% (5/26) 17% (4/23) 33% (1/3) 
*All of these recorded one of the categories above as well as additional training. 
** This data comes from administered questionnaire, and is not equivalent to “Prior Arrest or 
Charge” from Table 1, which was taken from baseline Addiction Severity Index.  
***Patients were asked to rate their knowledge of tuberculosis, risk of tuberculosis, and effort to 
prevent tuberculosis on a scale of 1-5.  
Acronyms: IQR = Interquartile range; SD = Standard Deviation; TSH = Tanzanian Shillings 
 
TB Active Case-Finding: 
Of the 150 surveyed, 16 (11%) had one or more symptoms and were referred for 
laboratory testing (see Table 3). The sputum sample from 1 patient was AFB-positive on 
sputum smear, and subsequently culture-positive. Culture of sputum samples from the 
remaining 15 smear-negative patients revealed that 5 grew TB. Additionally, 1 patient 
was found to have a Mycobacterium Other Than Tuberculosis (MOTT). On Drug 
Susceptibility Testing (DST) of culture-positive cases, 1 patient was found to have MDR-
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TB. Of note, this MDR patient’s sputum was smear-negative. The sputum sample for 1 
smear-negative, culture-positive patient was contaminated during DST. All patients 
identified with TB had a cough greater than two weeks, producing sputum. Of the 13 
patients reporting cough, 6 (46%) had TB. All patients who reported hemoptysis were 
found to have TB.  
 
Overall, 6 new cases of TB were identified in this active case finding program with a 
prevalence of 4%, or 4000 per 100,000 (see Table 3). The demographics of those with 
and without TB are presented in Table 2. Of importance, 5 patients with TB (83%) lived 
with, on average, 4.6 other individuals. Additionally 5 patients (83%) had a history of 
incarceration. Three patients were HIV-infected, while two were HIV-negative, with the 
remaining patient having an unknown HIV status. Three of the patients reported a prior 
history of TB; two of these (67%) reported completing the previous course of treatment, 
while one defaulted from treatment.  
Table 3:  Tuberculosis laboratory testing results of patients on methadone treatment at 
Muhimbili Medication Assisted Treatment Program, Dar es Salaam, Tanzania 
Characteristic n  (%) 
Total Patients Surveyed 150  
     Symptom Positive 16/150  (11%)  
          Smear-Positive, Culture-Positive 1/16  (6%) 
          Smear-Negative, Culture-Positive* 5/16  (31%) 
          Smear-Negative, Culture-Negative 10/16  (63%) 
     Total New Cases 6/150  (4%) 
          Multi-Drug Resistant** 1/6  (17%) 
*On sputum culture, one patient with an unknown HIV status was found to have Mycobacterium 
Other Than Tuberculosis (MOTT). This patient was not considered a positive case, but may have 
an opportunistic infection.  
**One sputum sample was contaminated during DST. 
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Discussion: 
Our study met our goals by identifying undiagnosed pulmonary TB cases and link them 
to treatment; assessing the prevalence of active pulmonary TB in this population; 
determining the prevalence of HIV/TB coinfection; determining the proportion of cases 
with MDR-TB; determining the proportion of cases that are smear-positive; and 
describing characteristics of TB cases. 
 
In our sample of 150 PWID on methadone maintenance, 4% (4000 per 100,000) had 
active pulmonary TB. This is roughly 23 times the national Tanzanian TB prevalence of 
172 per 100,000.(22) Of these 6 cases, 5 cases were smear-negative, and one smear-
negative case had MDR-TB. To our knowledge, this study represents the first data on TB 
in a population of PWID in Tanzania.  
 
Our results have significant implications for TB control in this population. Tanzanian 
PWID are a subpopulation at high risk for TB, and should be actively screened. If passive 
case finding alone had continued, these individuals would have been undiagnosed for a 
longer period of time, with potentially lethal consequences. With the high frequency of 
cohabitation, these individuals were also at risk for infecting household contacts. As 
methadone patients are required to attend the clinic 7 days a week, these undiagnosed 
cases also presented a transmission risk to other MAT clients and their healthcare 
providers. The original layout of the clinic’s waiting area lead to crowded conditions that 
allowed for ample opportunity for airborne transmission. The high proportion of patients 
with active pulmonary TB prompted the clinic staff to modify the structure of the waiting 
	  	  
31	  
room to increase ventilation. Thus the program was beneficial for both cases and their 
regular contacts, including patients and staff.  
 
Comparison with other case finding and prevalence studies in Tanzania 
Other Tanzanian studies on active TB have been performed in different populations with 
varying rates of TB.(47-53) For example, Munseri and colleagues examined a cohort of 
1318 subjects in 2 voluntary counseling and testing (VCT) centers in Dar es Salaam in 
2002-2003. One of these VCT centers was based at Muhimbili National Hospital, the 
same site where our study was implemented. Defining TB by both laboratory and clinical 
criteria, TB was present in 101 (7.7%) subjects, of whom 38 (38%) were already known 
TB cases and 63 (62%) were newly diagnosed. TB/HIV co-infection was detected in 70 
(5.3%) of subjects. Limiting to laboratory-confirmed cases, 35 of 1280 (2.7%) of subjects 
with an unknown TB status were culture-positive, which is slightly lower than our 
microbiologically confirmed prevalence of 4%.(52) 
 
Other studies have looked specifically at TB in HIV-positive populations in Tanzania. 
For example, Peck and colleagues followed a cohort of 2514 HIV-positive adults starting 
ART therapy at Bugando Medical Centre in Mwanza, Tanzania. Subjects did not have 
evidence of TB at the beginning of the study, and had monthly screenings for 6 months 
after starting ART. TB diagnosis was established by either microbiologic confirmation or 
by symptoms and chest radiographic findings consistent with TB, along with a positive 
response to anti-TB therapy. Although sputum smear microscopy was used, sputum 
culture was not available. Of the 2514 cases, 72 (3%) subjects were diagnosed with TB, 
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of which 66 (92%) subjects had pulmonary TB. Eleven  (0.4% of cohort) subjects were 
smear-positive, and the rest of the cases were smear-negative but had clinical criteria 
consistent with TB.(48) 
 
Comparison with other active TB studies in methadone clinics 
Case finding studies for TB in methadone clinics have not been performed in Africa to 
date; however, they have been performed elsewhere.(54-58) In the pre-HIV era of the 
1970s, Reichman and colleagues surveyed PWID enrolled in 20 citywide clinics in the 
New York City Methadone Maintenance Treatment Program. Subjects received TST for 
latent TB, and TST-positive subjects were referred to the health department for clinical 
evaluation and chest x-ray. Of 3818 subjects, 853 (22.5%) were TST-positive, and 52 
(1.4%) had chest x-rays consistent with active TB.  
 
After the advent of HIV in the late 1980s, Selwyn and colleagues prospectively studied 
520 PWID enrolled in a methadone-maintenance program in the Bronx, New York. They 
screened all subjects on admission for HIV and for latent TB with Tuberculin Skin 
Testing (TST), and then followed them prospectively for development of latent TB or 
active TB for a mean of 22 months. At baseline, 217 (42%) were HIV-positive, and forty-
nine of 217 (23%) HIV-positive subjects had a positive TST, compared to 62 of 303 
(20%) HIV-negative subjects.  Among those who had a negative PPD at the beginning of 
the study, a conversion to positive PPD at follow-up was seen in 15 of 131 (11%) HIV-
positive subjects and 26 of 202 (13%) HIV-negative subjects. These rates did not 
significantly differ. However, the HIV-positive group was much more likely to develop 
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active TB: eight of the 215 (4%) HIV-positive subjects developed active TB within the 
follow-up period, and none of the HIV-negative group developed active TB. Among 
those HIV-positive subjects who had a positive PPD at enrollment, 7 of 49 (14%) 
developed active TB. Among our study’s 6 cases, 1 was HIV-negative in the last 3 
months, and the other 5 were either HIV-positive or had an unknown status. (55) 
 
More recently, Ruutel and colleagues studied a cohort of 112 PWID at a methadone 
program in Estonia in 2007. They tested all eligible and consenting patients for HIV, and 
for latent TB with TST and interferon-gamma release assay (IGRA). Of all subjects, 
(86%) were HIV-positive, 17% were TST-positive, and 7.4% were IGRA positive. Of the 
49 (43.8%) subjects who attended the TB clinic, none were diagnosed with active 
TB.(58)  
 
Recently, two papers from Iran studied PWID in methadone programs. From 2008 to 
2009, Mamani and colleagues surveyed 268 PWID in methadone maintenance programs 
in the city of Hamedan. About 30% of the subjects were HIV-positive. TST was 
performed on all patients. For patients with positive TST, chest x-ray and sputum smear 
microscopy was performed. TST was positive in 18.3% of subjects, and one case of 
active TB was diagnosed by chest x-ray and sputum smear.(59) From 2011-2012, 
Honarvar and colleagues surveyed 263 opiate users who attended university affiliated 
drop-in centers, methadone maintenance clinics, and harm-reduction facilities in southern 
Iran. About 75% were PWID, and the others were non-injectors. About 84% were on 
methadone, and about 56% were HIV-positive. All received a symptom screen, and all 
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symptomatic patients received sputum microscopy, sputum culture and chest x-ray. Three 
(1%) culture-positive cases were found, two of which were smear-positive, and 1 of 
which was in a PWID. The prevalence among PWID was 500 per 100,000, about one-
eighth the prevalence in our study.(60) 
 
Smear-Positivity: 
In our study, 5 of 6 (83%) of the newly diagnosed cases were missed by sputum smear 
and identified only by sputum culture. One potential explanation for this finding is that 
HIV-infected individuals are more likely to have sputum-smear negative TB.(14) Two 
studies among HIV-infected patients within Tanzania have shown smear sensitivity of 
40%(53) and 61.8%(50). Of our 5 smear-negative, culture-positive patients, 2 were 
known to be HIV-infected, and 2 had an unknown HIV status. Our results suggest that 
sputum culture be included in all active screening programs of PWID. Of critical 
importance, it took several weeks to reach a diagnosis for these smear-negative patients. 
These patients continued to pose an infection risk during this diagnostic delay, 
highlighting the need for rapid diagnostics in screening programs, such as the nucleic 
acid-based testing. Due to these results, the MAT clinic plans to invest in a GeneXpert 
array when resources are available.  
 
Symptom Screen: 
Our symptom analysis showed that cough greater than 2 weeks and sputum production 
were the most sensitive symptoms, with all new diagnoses having these symptoms. This 
is consistent with other studies, which have successfully used cough > 2-3 weeks as the 
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only symptom screen.(61) At Muhimbili National Hospital, the same site where our study 
was implemented, Mwita and colleagues surveyed 125 HIV-infected patients with cough 
in 2006. Screening was sputum smear with Ziehl-Neelsen stain, but no culture was 
performed. They found nine subjects (7.2%) with smear-positive TB.(47) This is similar 
to 1 of 13 (7.7%) patients with cough in our study, although 6 of 13 (46%) were culture-
positive, suggesting that Mwita and colleagues may have found more patients if they had 
been able to culture sputum samples. Although cough greater than 2 weeks was 100% 
sensitive among the patients tested in our study, our protocol did not identify 
asymptomatic cases, so the sensitivity among the entire study population cannot be 
calculated.  
 
Characteristics of Population and TB Cases: 
Our study found several interesting characteristics of TB cases. First, five out of 
six patients with active TB in our sample lived with others, suggesting that household 
contacts were at increased risk for transmission. A 2009 study by Kifai and Bakari from 
Dar es Salaam found Mantoux skin test reactivity in more than 60% of household 
contacts of smear-positive cases.(62) Another study by Ntinginya and colleagues used the 
Cepheid Xpert MTB/RIF assay to conduct case finding among household contacts of TB 
cases in Mbeya, Tanzania. Among 219 patients surveyed, the prevalence of active TB 
was 2.3%.(63) The detection of at least one MDR-TB case in our sample makes the 
potential for transmission beyond the PWID community even more worrisome.   
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Additionally, there was a very high rate of past TB history in the population as a whole 
(17%), and even higher among patients currently infected with TB (38%). There is 
evidence of high rates of recurrent TB in Tanzania. For example, Lahey and colleagues 
examined a cohort of 979 HIV-infected, BCG-immunized adults with CD4 counts >= 200 
cells/uL who received placebo in a TB vaccine trial in Tanzania. Among 80 subjects who 
reported prior active TB, 11 (13.8%) subsequently developed definite TB and 17 (21.3%) 
definite/probable TB during a median follow-up of 3.2 years.(49) This is similar to our 
rate of 11.5% (3 of 26).  
 
In our study, a very high rate of patients had been previously incarcerated or held in pre-
trial detention (71%), which may have served as a major transmission site for PWID. A 
study by Rutta and colleagues in the mid-1990s investigated prisoners at Bugando 
Medical Centre in Mwanza, Tanzania which receives referrals from all ill prisoners at 
nearby Butimba Prison. The investigators performed a chart review of all prisoners with 
TB. Of 625 prisoners diagnosed with TB over a 3-year period, 501 cases had complete 
patient records, of which 204 (40.7%) cases were smear-positive, suggesting a high 
proportion of TB cases were infectious. This suggests that Tanzanian prisons may be a 
high-yield site for case finding.  
 
Limitations: 
Our study has several limitations. First, our study used a small nonrandom sample, and 
was susceptible to selection bias. Our sample had a significantly higher known HIV-
positivity rate than unenrolled patients. There are two potential explanations. First, chart 
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review was more thorough for patients in the sample, taking into account patient’s self-
report of positive status, while chart review for unenrolled patients was limited to 
registration data and laboratory testing. Second, patients who refused or avoided 
recruitment into our study may have also been more likely to refuse HIV testing, and may 
have had undiagnosed HIV infection.   
 
Another limitation was laboratory testing only symptomatic patients (with an emphasis 
on pulmonary symptoms), missing asymptomatic cases and those with extra-pulmonary 
TB. Although the study by Getahun and colleagues(41) mentioned in the introduction 
showed that HIV-positive patients without the four key symptoms had a very low 
probability of having active TB disease, some small studies in Tanzania have discovered 
asymptomatic cases. For example, a prevalence study of 93 HIV patients in Dar es 
Salaam by Mtei and colleagues found 4 of 14 cases had no symptoms or chest x-ray 
findings consistent with TB.(51) In another study by Ngowi and colleagues of 233 
patients in a rural Tanzanian HIV clinic, 75% of the 20 cases discovered had no 
symptoms or chest x-ray findings consistent with TB.(53) Without data on these potential 
asymptomatic cases, we could not calculate sensitivity and specificity of our screening 
questions for the entire study population.   
 
Third, 69% of the sample had an unknown HIV status, which limited our ability to 
analyze rates of HIV-TB co-infection in this population. Fourth, the majority of our 
patients were male, and our data provides limited insight into TB among female injectors. 
This represents the gender distribution of the clinic as a whole, which had difficulty 
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recruiting female injectors. Next, we defined a TB case as smear or culture positive 
sputum – this may underestimate the TB prevalence in the MAT program in comparison 
with national prevalence rates that include cases that are clinically diagnosed and not 
microbiologically confirmed.  
Finally, the scope of our study did not look at outcomes between patients identified by 
passive vs. active case finding to observe an impact on mortality, which would be the true 
sign of success of the screening program.  
 
Future Steps:  
This pilot study suggests high rates of active TB in PWID entering this methadone clinic, 
and all future clients should be screened at entry, at a minimum using a symptom screen 
with sputum smear and culture. If resources are found to conduct sputum testing on all 
patients at registration, it may provide information on asymptomatic cases. The MAT 
clinic has continued to screen patients with a symptom screen after the conclusion of this 
project, and has found a substantially increased prevalence. Over 50 patients have 
completed or are currently undergoing TB treatment along with daily methadone. 
Treatment outcomes should be evaluated and improved.   
 
Additionally, as our data showed that many TB cases lived with several other people, 
future efforts should attempt contact tracing in the community. Household contact cases 
should be linked to directly-observed treatment to decrease community transmission. 
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Finally, the clients participating in the MAT program were selected based on their 
motivation and likelihood to succeed in methadone treatment; therefore, it is reasonable 
to believe that they represent a healthier subset of the larger PWID population, who may 
have a higher burden of HIV and TB. Future studies should attempt case finding in the 
community, potentially with the help of community-based NGOs and community 
outreach vans run by the Tanzanian AIDS Prevention Programme.     
 
Finally, as TB and HIV treatment were delivered together with methadone, treatment 
outcomes should be studied to quantify benefits from this integrated approach to care for 
PWID.  
 
Conclusion: 
In conclusion, this pilot study actively screened 150 people who inject drugs who were 
started on methadone in Dar es Salaam, Tanzania and found that 6 patients had sputum 
cultures indicative of active TB. This TB prevalence of 4% is 23 times higher than the 
national prevalence of TB in Tanzania. Our study suggests sputum culture and DST 
should be obtained on all patients with a cough greater than 2 weeks, productive of 
sputum. Ongoing efforts to identify PWIDs with TB must be undertaken and effective 
treatment programs must be established to assist patients in completing treatment 
integrated with their methadone and antiretroviral therapy. 
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